ARCHIVES

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 1 | January 31, 2014

Download PDF Visit The Full Archive

Related Articles

Senate Votes Down Attempt to Cut NCI Funds $100 Million

October 3, 1975

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004

Other ASCO Plenary Papers: Long Awaited Chemotherapy Results

June 12, 1992

Drug Development: ODAC Discussion May Offer Clues For Sponsors of Cytostatic Drugs

June 16, 1999

Gerstner Resigns From NA, MSK Board After Taking RJR Job

March 24, 1989

GAO Recommends Tighter Policies on NIH Recusals.

June 29, 2007